Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition
Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fl
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the reported Q2 revenue, Adjusted EPS, Adjusted EBITDA, and the reaffirmed full-year Adjusted EBITDA range. The filing also highlights drivers (reimbursement mix, collections, payor mix) and offsets (same-unit volume decline) plus cash flow and leverage context.
Market read
A fresh earnings release with specific quarterly numbers and a reaffirmed full-year EBITDA range provides actionable inputs for valuation and positioning.
What to watch
Cash from continuing operations fell year over year ($126.3M vs $138.1M), and cash balances declined materially from Dec 31, 2025 ($375.2M to $288.9M), which may temper enthusiasm even with EBITDA guidance reaffirmed.
Background
This is Pediatrix Medical Group’s SEC Form 8-K (Item 2.02) with Q2 2026 operating results and financial condition, including a reaffirmed full-year 2026 Adjusted EBITDA outlook.
Ticker impact
Pediatrix reported Q2 2026 results, including Adjusted EPS of $0.63 and reaffirmed full-year 2026 Adjusted EBITDA guidance of $280M to $300M.
Near-term bias upward if investors view same-unit reimbursement and acquisition integration as durable; watch cash flow and same-unit volume softness.
The filing provides concrete quarterly datapoints (revenue, net income, Adjusted EPS, Adjusted EBITDA) plus a specific reaffirmed full-year EBITDA range, which are direct inputs to valuation and forward expectations.
Market effects
Reinforces that physician services operators can grow via acquisitions and reimbursement mix, potentially supporting sector sentiment around managed-care contracting and collections.
No explicit regional impact beyond company-specific performance.
Primarily US healthcare services; limited direct global read-through from the filing.
Counterpoint
Despite improved reimbursement metrics, same-unit patient volume declined (down 2.1%), which could pressure future growth if volume weakness persists.
Key entities
- issuerPediatrix Medical Group, Inc.
Reports Q2 2026 results, cash flow, debt levels, and reaffirms full-year 2026 Adjusted EBITDA guidance.
- executiveMark S. Ordan
CEO quoted attributing results to acquisition performance and same-unit reimbursement metrics.
- executiveKasandra H. Rossi
CFO and Treasurer listed as contact for the release.
